药石科技(300725) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was ¥285,807,823.32, representing a 67.55% increase compared to ¥170,584,228.47 in the same period last year[8] - Net profit attributable to shareholders was ¥69,771,989.47, a significant increase of 147.31% from ¥28,212,630.51 year-on-year[8] - The net profit after deducting non-recurring gains and losses was ¥64,659,819.15, up 152.22% from ¥25,636,226.95 in the previous year[8] - Basic and diluted earnings per share were both ¥0.45, reflecting a 136.84% increase compared to ¥0.19 in the previous year[8] - The company's gross profit margin for Q1 2021 was 47.47%, down from 51.59% in Q1 2020, indicating a potential risk of margin decline[37] - The total operating revenue for the first quarter was CNY 285,807,823.32, an increase of 67.5% compared to CNY 170,584,228.47 in the previous period[75] - Net profit for the quarter reached CNY 69,771,813.76, compared to CNY 28,212,434.60 in the same period last year, representing a growth of 147.5%[81] - Operating profit for the current period was ¥52,219,559.23, up from ¥26,464,532.00, reflecting a growth of 97.5%[89] - Net profit for the current period was ¥50,061,187.43, compared to ¥25,545,921.17 in the previous period, indicating a year-over-year increase of 96.2%[89] Cash Flow - The net cash flow from operating activities reached ¥157,685,994.56, marking a 198.13% increase from ¥52,891,683.93 in the same quarter last year[8] - Cash flow from operating activities totaled ¥157,685,994.56, up from ¥52,891,683.93, representing a growth of 197.5%[97] - The company reported a significant increase in cash inflow from sales of goods and services, totaling ¥402,970,635.81 compared to ¥202,111,978.73 in the previous period, an increase of 99.4%[93] - Total cash inflow from operating activities was ¥552,969,700.02, significantly higher than ¥215,244,906.41 in the prior period, indicating a growth of about 157.5%[100] - Cash outflow from operating activities totaled ¥489,207,976.79, compared to ¥154,432,217.22 in the previous period, representing an increase of approximately 216.5%[100] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,530,257,030.14, a 4.33% increase from ¥2,425,289,638.00 at the end of the previous year[8] - The total assets of the company increased to CNY 2,510,580,384.80 from CNY 2,490,060,532.47, showing a growth of 0.8%[75] - Current liabilities increased to approximately ¥496.9 million from ¥475.9 million, a rise of about 4.4%[65] - The total liabilities amounted to approximately ¥555.3 million, up from ¥530.6 million, representing an increase of about 4.7%[65] - Owner's equity rose to CNY 1,930,575,680.72, up from CNY 1,870,105,690.26, reflecting an increase of 3.2%[75] Research and Development - The company increased its R&D expenses by 73.18% to CNY 29.42 million, reflecting a commitment to innovation[24] - Research and development expenses were CNY 29,415,589.37, which is an increase of 73.5% from CNY 16,985,603.04 in the previous year[78] - The company plans to focus on small molecule drugs and enhance its R&D platform over the next three years[29] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,563[12] - The largest shareholder, Yang Minmin, held 20.68% of the shares, totaling 31,774,630 shares[12] Government Support and Subsidies - The company received government subsidies amounting to ¥3,829,399.99 during the reporting period[8] Market and Competition - The company is facing intensified market competition but aims to maintain its competitive edge through increased R&D investment and service capability enhancement[35] - The company emphasizes the importance of monitoring regulatory changes in the pharmaceutical industry to mitigate operational risks[35] Investment Activities - The company plans to issue 8,385,650 shares at a price of ¥111.50 per share, raising a total of ¥934,999,975.00, with a net amount of ¥928,090,177.20 after expenses[40] - The acquisition of a 16.5% stake in Zhejiang Huishi Pharmaceutical Co., Ltd. will increase the company's ownership to 53.93%, making it a subsidiary[41] Risk Management - Environmental protection and safety production measures are in place to mitigate risks associated with waste management and operational hazards[36] - The company is exposed to foreign exchange risks due to a high proportion of sales in foreign currencies, with strategies in place to hedge against these risks[37]